225Ac-DOTA-LM3 Research for Lu-177 Refractory NETs
An evidence-based overview of research examining 225Ac-DOTA-LM3 in the context of lu-177 refractory nets. This page synthesizes findings from peer-reviewed literature.
Research Summary
Patients progressing after Lu-177 DOTATATE have limited options. 225Ac-DOTA-LM3 addresses multiple resistance mechanisms: alpha particles cause irreparable DNA damage (vs repairable beta damage), and antagonist binding accesses more receptor sites. Case series report disease control in 80% of refractory patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. 225Ac-DOTA-LM3 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.